Sign in Subscribe

Topic

life science

A collection of 8 issues

Hologic to be acquired by private equity

Hologic, Inc., announced on 21 October 2025 that it has entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to US$79 per share, representing an enterprise value of up to US$18.3 billion. Under the terms

Illumina's acquisition of Somalogic is a clear IP play

Illumina announced on 23 June 2025 that it will acquire SomaLogic from Standard BioTools, for US$350 million cash plus up to US$75 million in performance-based payments, reinforcing its multiomics roadmap by embedding high-plex proteomics into its sequencing operations. The transaction, expected to close in the first half of

Lilly hedges IP risk in $1.3bn Verve acquisition

Eli Lilly has announced its intention to acquire Verve Therapeutics for approximately US$1.3 billion, aiming to accelerate development of one-time gene-editing treatments for cardiovascular disease. The acquisition builds on a pre-existing collaboration between the two companies focused on in vivo gene editing and positions Lilly to compete more

Regeneron acquires 23andMe to access DNA profiling IP

Regeneron Inc has announced it has entered into an Asset Purchase Agreement to acquire 23andMe for US$ 256 Million. The planned purchase aims to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases. Regeneron has stated that it plans to: * maintain the

Cortigent’s Patent Portfolio: Aging IP or Strategic Reset?

Vivani Medical has announced plans to spin off Cortigent as an independent publicly-traded company. The spin-off is planned to be completed by Q3 2025. Vivani Medical was formed in 2022 through the merger of Second Sight Medical and Nano Precision Medical. Cortigent, previously known as Second Sight Medical Products, has

2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal

2Seventybio has announced a definitive merger agreement under which Bristol Myers Squibb (BMS) will acquire the company in an all-cash transaction for a total equity value of approximately US$ 286 million. The transaction has been approved by both companies and is expected to close in Q2 of this year. 2Seventybio

Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash

Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close in Q2 of this year. The acquisition sees Jazz Pharmaceuticals gain

Bluebird bio to be acquired by Carlyle and SK Capital